샘플 요청 목록

 카트 문의
시장보고서
상품코드
1782998

세계의 펩타이드 항생제 시장

Peptide Antibiotics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 381 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

펩타이드 항생제 세계 시장은 2030년까지 61억 달러에 달할 전망

2024년에 48억 달러로 추정되는 펩타이드 항생제 세계 시장은 2024년부터 2030년까지 CAGR 3.9%로 성장하여 2030년에는 61억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 비리보솜 합성 펩타이드 항생제는 CAGR 4.6%를 기록하며 분석 기간 종료까지 43억 달러에 달할 것으로 예측됩니다. 리보솜 합성 펩타이드 항생제 분야의 성장률은 분석 기간 동안 CAGR 2.5%로 추정됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 7.4%로 성장 예측

미국의 펩타이드 항생제 시장은 2024년에 13억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 12억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.6%와 3.1%로 예측됩니다. 유럽에서는 독일이 CAGR 2.3%로 성장할 것으로 예측됩니다.

세계의 펩타이드 항생제 시장 - 주요 동향과 촉진요인 정리

펩타이드 항생제란?

펩타이드 항생제는 펩타이드로 알려진 짧은 아미노산 사슬로 구성된 항생제의 일종으로 항균 특성을 가지고 있습니다. 이러한 천연 또는 합성 펩타이드는 박테리아, 곰팡이 및 기타 병원균에 대해 광범위한 스펙트럼의 활성을 보여 기존의 저분자 항생제를 대체할 수 있는 중요한 대안이 될 수 있습니다. 펩타이드 항생제는 일반적으로 미생물의 세포막을 파괴하여 세포 용해와 사멸을 유발하는 방식으로 작용합니다. 펩타이드 항생제는 세균막에 결합하여 구멍을 뚫고 세포 내용물을 누출시켜 결국 세균을 사멸시킵니다. 또한, 일부 펩타이드 항생제는 특정 세포 내 경로를 표적으로 삼아 단백질 합성 및 기타 필수 세포 기능을 억제하는 경우도 있습니다.

주로 특정 박테리아의 효소나 경로를 표적으로 삼는 기존 항생제와 달리, 펩타이드 항생제는 다제내성균을 포함한 보다 광범위한 병원균을 공격할 수 있는 보다 다재다능한 항생제인 경우가 많습니다. 따라서 펩타이드 항생제는 세계 보건 위기가 되고 있는 항생제 내성 문제를 해결하는 데 특히 유용합니다. 펩타이드 항생제는 디펜신, 마게닌, 반코마이신과 같은 천연물이나 유효성과 안정성을 향상시키기 위해 실험실에서 설계된 합성 펩타이드 등 다양한 형태로 발견되고 있습니다. 이 항생제들은 기존 항생제가 잘 듣지 않는 감염, 특히 내성균에 의한 감염 치료에 유망한 것으로 평가받고 있습니다.

펩타이드 항생제 시장이 확대되는 이유는 무엇일까?

펩타이드 항생제 시장은 항생제 내성 감염의 증가, 의료 관련 감염(HAI) 발생률 증가, 다제내성 병원체 치료에서 현재 항생제의 한계로 인해 확대되고 있습니다. 항생제 내성은 공중보건의 가장 심각한 문제 중 하나로 떠오르고 있습니다. 박테리아 및 기타 병원균이 기존의 많은 항생제를 견딜 수 있도록 진화해 왔기 때문입니다. 이러한 내성으로 인해 보다 효과적인 새로운 치료법 개발이 시급한 상황이며, 내성 감염에 대한 유망한 해결책으로 펩타이드 항생제가 큰 주목을 받고 있습니다.

의료 관련 감염(HAI)의 증가도 펩타이드 항생제 시장을 이끄는 요인 중 하나입니다. 병원 내에서 발생하여 수술을 받는 환자에게 영향을 미치는 이러한 감염은 종종 약제 내성균에 의해 발생하며, 환자의 건강에 심각한 위험을 초래합니다. 이러한 상황에서 펩타이드 항생제는 메티실린 내성 황색포도상구균(MRSA), 클로스트리듐 디피실(C. difficile) 등 병원에서 흔히 볼 수 있는 내성균에 대한 효과가 입증되어 잠재적인 치료 옵션으로 검토되고 있습니다. 펩타이드 항생제는 기존 항생제에 내성이 있는 박테리아를 포함한 광범위한 박테리아를 표적으로 삼을 수 있기 때문에 치료가 어려운 감염성 질환에 대처할 수 있는 귀중한 도구가 될 수 있습니다.

또한, 펩타이드 기반 치료제에 대한 관심이 높아지고 펩타이드 합성 및 약물전달 기술의 발전으로 새로운 펩타이드 항생제 개발이 촉진되고 있습니다. 이러한 발전으로 더 강력하고 안정적인 펩타이드 항생제 생산이 가능해져 치료 가능성이 넓어지고 표준 항생제에 내성을 갖게 된 감염증의 치료 능력이 향상되고 있습니다. 제약 업계가 새로운 펩타이드 항생제를 발견하기 위해 연구개발에 지속적으로 투자하고 있기 때문에 이러한 치료 시장은 성장할 것으로 예상됩니다.

펩타이드 항생제의 미래를 좌우할 주요 동향은?

펩타이드 항생제 시장의 미래는 항생제 내성에 대한 지속적인 관심, 펩타이드 설계 및 제형의 발전, 병용요법의 일부로 펩타이드의 사용 증가 등 몇 가지 주요 동향에 의해 형성될 것입니다. 주요 동향 중 하나는 항균제 내성(AMR)의 증가에 대응하기 위한 신규 펩타이드 항생제의 발견과 개발에 중점을 두고 있다는 점입니다. 세계 각국의 정부와 의료 기관은 다제내성 병원균의 위협에 대응하기 위해 펩타이드 기반 약물을 포함한 새로운 항생제 개발을 장려하는 노력에 투자하고 있습니다. 이러한 추세는 내성 감염에 대응하는 방법으로 펩타이드 항생제의 가능성에 대한 연구를 증가시키고 있습니다.

펩타이드 설계와 제형화의 발전 또한 시장의 미래를 크게 좌우하고 있습니다. 연구진은 반감기가 짧고 인체 내에서 쉽게 분해되는 펩타이드 항생제의 안정성, 생체 이용률, 안전성 프로파일을 개선하는 데 주력하고 있습니다. 펩타이드 유사체, 펩타이드 모방체, 접합체 개발과 같은 새로운 전략을 통해 과학자들은 이러한 한계를 극복하고 펩타이드 항생제의 임상적 유용성을 향상시킬 수 있습니다. 또한, 나노입자, 리포솜 등 약물전달 기술의 발전으로 펩타이드 항생제의 효율과 타겟팅이 개선되어 감염성 질환 치료에 더욱 효과적일 수 있게 되었습니다.

또 다른 새로운 트렌드는 펩타이드 항생제를 다른 항균제나 치료법과 함께 사용하는 것에 대한 관심이 높아지고 있다는 점입니다. 병용요법이란 펩타이드 항생제를 기존 항생제나 다른 계열의 약제와 함께 사용하여 치료 성적을 향상시키고 내성균 대책에도 도움이 되는 것을 말합니다. 서로 다른 작용기전을 이용하여 병용요법은 치료효과를 높이고 내성균의 발생을 억제하며, 각 약물의 용량을 줄여 부작용을 최소화할 수 있습니다. 이러한 추세는 특히 중증 및 다제내성 감염 치료에서 펩타이드 항생제의 임상적 성공률을 향상시킬 수 있는 방법을 연구자들이 지속적으로 모색하고 있기 때문에 더욱 힘을 얻고 있습니다.

펩타이드 항생제 시장의 성장 촉진요인은?

펩타이드 항생제 시장의 성장은 항생제 내성 감염증의 증가, 만성질환의 증가, 펩타이드 합성 기술의 발전 등 여러 요인에 의해 이루어집니다. 항생제 내성 증가는 펩타이드 항생제 수요에 기여하는 가장 중요한 요인 중 하나입니다. 기존 항생제가 내성 병원균에 대한 효과를 잃어가고 있는 가운데, 펩타이드 항생제는 이 문제에 대한 잠재적인 해결책을 제시합니다. 펩타이드 항생제는 기존 치료제에 내성을 가진 박테리아를 포함한 광범위한 박테리아 종을 표적으로 삼을 수 있다는 점이 시장 성장의 주요 촉진요인으로 작용하고 있습니다.

항생제 내성 외에도 만성질환과 병원내 감염의 증가는 새로운 항생제 치료에 대한 수요를 증가시키고 있습니다. 당뇨병이나 암과 같은 만성질환은 장기 입원이나 수술이 필요한 경우가 많아 내성균에 의한 감염 위험이 높아집니다. 펩타이드 항생제는 광범위한 스펙트럼의 활성과 치료하기 어려운 병원균을 표적으로 삼을 수 있는 능력을 가지고 있어, 이러한 환경에서 잠재적인 치료 옵션으로 검토되고 있습니다. 전 세계 인구의 고령화와 만성질환의 부담이 계속 증가함에 따라, 이러한 취약 계층의 감염증을 관리하기 위한 효과적인 치료법에 대한 요구가 펩타이드 항생제 시장을 견인할 것으로 예상됩니다.

펩타이드 합성 기술의 발전도 시장 성장에 기여하고 있습니다. 최근 고체상 펩타이드 합성(SPPS)의 혁신으로 펩타이드의 효율적이고 확장 가능한 생산이 가능해짐에 따라 펩타이드 항생제는 제약회사들이 보다 쉽게 이용할 수 있게 되었으며, 비용 효율성도 향상되었습니다. 이를 통해 효능과 안전성이 개선된 차세대 펩타이드 항생제가 개발되었습니다. 또한, 제약회사와 학술기관의 연구개발에 대한 투자 증가는 새로운 펩타이드 항생제 발견을 가속화하고 치료 가능성을 넓혀 시장을 발전시키는 데 도움이 되고 있습니다.

마지막으로, 생물학적 제제의 수용과 맞춤형 의료에 대한 관심이 높아지면서 펩타이드 항생제에 새로운 기회를 가져다주고 있습니다. 헬스케어 산업이 보다 표적화된 맞춤형 치료로 전환하고 있는 가운데, 펩타이드 항생제는 보다 특이적이고 부작용이 적은 광범위한 감염성 질환을 치료할 수 있는 유망한 접근법을 제공합니다. 펩타이드 기반 치료법에 대한 연구가 확대됨에 따라 펩타이드 항생제가 맞춤형 치료 요법에 사용될 가능성은 계속 확대될 것이며, 시장 수요는 더욱 증가할 것입니다.

부문

제품 유형(비리보솜 합성 펩타이드 항생제, 리보솜 합성 펩타이드 항생제), 질환 유형(피부 감염증, HABP/VABP, 혈류 감염, 기타 질환 유형), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례

  • AbbVie Inc.
  • Acurx Pharmaceuticals
  • ANI Pharmaceuticals, Inc.
  • Antabio
  • BiomX
  • Clarametyx Biosciences
  • Cubist Pharmaceuticals(acquired by Merck & Co.)
  • Cumberland Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GSK plc.
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • MinervaX
  • Pfizer Inc.
  • Sandoz AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • The Menarini Group
  • Venatorx Pharmaceuticals
  • Xellia Pharmaceuticals

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.12

Global Peptide Antibiotics Market to Reach US$6.1 Billion by 2030

The global market for Peptide Antibiotics estimated at US$4.8 Billion in the year 2024, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Non-ribosomal Synthesized Peptide Antibiotics, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Ribosomal Synthesized Peptide Antibiotics segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 7.4% CAGR

The Peptide Antibiotics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Peptide Antibiotics Market - Key Trends & Drivers Summarized

What Are Peptide Antibiotics and How Do They Work?

Peptide antibiotics are a class of antibiotics composed of short chains of amino acids, known as peptides, that have antimicrobial properties. These naturally occurring or synthetic peptides exhibit broad-spectrum activity against bacteria, fungi, and other pathogens, making them an important alternative to traditional small-molecule antibiotics. Peptide antibiotics typically function by disrupting the microbial cell membrane, thereby causing cell lysis and death. They can bind to bacterial membranes and create pores, leading to leakage of cellular contents, which ultimately kills the bacteria. Additionally, some peptide antibiotics target specific intracellular pathways, inhibiting protein synthesis or other essential cellular functions.

Unlike traditional antibiotics that primarily target specific bacterial enzymes or pathways, peptide antibiotics are often more versatile, capable of attacking a wider range of pathogens, including multidrug-resistant bacteria. This makes them particularly valuable in addressing the growing concern of antibiotic resistance, which has become a global health crisis. Peptide antibiotics are found in a variety of forms, including natural products such as defensins, magainins, and vancomycin, as well as synthetic peptides designed in laboratories to improve efficacy and stability. These antibiotics have shown promise in treating infections that do not respond well to conventional antibiotics, particularly those caused by resistant strains of bacteria.

Why Is the Peptide Antibiotics Market Expanding?

The peptide antibiotics market is expanding due to the rising prevalence of antibiotic-resistant infections, the increasing incidence of healthcare-associated infections (HAIs), and the limitations of current antibiotics in treating multidrug-resistant pathogens. Antibiotic resistance has emerged as one of the most critical public health challenges, as bacteria and other pathogens have evolved to withstand many of the existing antibiotics. This resistance has led to an urgent need for new and more effective treatments, and peptide antibiotics have gained significant attention as a promising solution to combat resistant infections.

The growing incidence of healthcare-associated infections (HAIs) is another driving factor for the peptide antibiotics market. These infections, which occur in hospital settings and affect patients undergoing surgeries, are often caused by drug-resistant bacteria and pose serious risks to patient health. In this context, peptide antibiotics are being explored as potential treatment options, as they have demonstrated effectiveness against resistant bacterial strains commonly found in hospitals, such as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. difficile). The ability of peptide antibiotics to target a broad range of bacteria, including those resistant to conventional antibiotics, makes them a valuable tool in addressing these difficult-to-treat infections.

Moreover, the growing interest in peptide-based therapeutics, as well as advancements in peptide synthesis and drug delivery technologies, has facilitated the development of new peptide antibiotics. These advances allow for the production of more potent and stable peptide antibiotics, expanding their therapeutic potential and enhancing their ability to treat infections that have become resistant to standard antibiotics. As the pharmaceutical industry continues to invest in research and development to discover novel peptide antibiotics, the market for these treatments is expected to grow.

What Key Trends Are Shaping the Future of Peptide Antibiotics?

The future of the peptide antibiotics market is shaped by several key trends, including the ongoing focus on antibiotic resistance, advancements in peptide design and formulation, and the increasing use of peptides as part of combination therapies. One of the major trends is the growing emphasis on discovering and developing novel peptide antibiotics to combat the rise of antimicrobial resistance (AMR). Governments and healthcare organizations worldwide are investing in initiatives to encourage the development of new antibiotics, including peptide-based drugs, as a response to the threat of multidrug-resistant pathogens. This trend is driving increased research into the potential of peptide antibiotics as a way to combat resistant infections.

Advancements in peptide design and formulation are also significantly shaping the market's future. Researchers are focusing on improving the stability, bioavailability, and safety profile of peptide antibiotics, which can often be limited by their short half-lives and susceptibility to degradation in the human body. New strategies, such as the development of peptide analogs, peptide mimetics, and conjugates, are enabling scientists to overcome these limitations and enhance the clinical utility of peptide antibiotics. Additionally, advancements in drug delivery technologies, such as nanoparticles and liposomes, are improving the efficiency and targeting of peptide antibiotics, making them more effective in treating infections.

Another emerging trend is the increasing interest in using peptide antibiotics in combination with other antimicrobial agents or therapies. Combination therapies, where peptide antibiotics are paired with traditional antibiotics or other classes of drugs, can improve treatment outcomes and help address resistance. By using different mechanisms of action, combination therapies can enhance the overall effectiveness of treatment, reduce the development of resistance, and allow for the use of lower doses of each drug, minimizing side effects. This trend is gaining traction as researchers continue to explore ways to improve the clinical success rates of peptide antibiotics, especially in the treatment of severe and multidrug-resistant infections.

What Are the Key Drivers of Growth in the Peptide Antibiotics Market?

The growth of the peptide antibiotics market is driven by several factors, including the increasing prevalence of antibiotic-resistant infections, the growing number of chronic diseases, and the advancements in peptide synthesis technologies. The rise of antibiotic resistance is one of the most significant factors contributing to the demand for peptide antibiotics. As traditional antibiotics lose their efficacy against resistant pathogens, peptide antibiotics offer a potential solution to this growing problem. The ability of peptide antibiotics to target a wide range of bacterial species, including those resistant to conventional treatments, is a major driver of their market growth.

In addition to antibiotic resistance, the increasing prevalence of chronic diseases and hospital-acquired infections is driving the demand for new antibiotic treatments. Chronic conditions such as diabetes and cancer often require long-term hospital stays and surgical interventions, which increase the risk of infections caused by resistant bacteria. Peptide antibiotics, with their broad-spectrum activity and ability to target difficult-to-treat pathogens, are being explored as potential treatment options in these settings. As the global population ages and the burden of chronic diseases continues to grow, the need for effective treatments to manage infections in these vulnerable populations is expected to drive the market for peptide antibiotics.

Advancements in peptide synthesis technologies are also contributing to market growth. Recent innovations in solid-phase peptide synthesis (SPPS), which enable the efficient and scalable production of peptides, have made peptide antibiotics more accessible and cost-effective for pharmaceutical companies. This has led to the development of a new generation of peptide antibiotics with improved efficacy and safety profiles. Furthermore, the increasing investment in research and development by pharmaceutical companies and academic institutions is helping to accelerate the discovery of new peptide antibiotics, expanding their therapeutic potential and driving the market forward.

Finally, the growing acceptance of biologics and the increasing interest in personalized medicine are providing new opportunities for peptide antibiotics. As the healthcare industry shifts toward more targeted and individualized treatments, peptide antibiotics offer a promising approach for treating a wide range of infections with greater specificity and fewer side effects. As research into peptide-based therapies expands, the potential for peptide antibiotics to be used in personalized treatment regimens will continue to grow, further fueling market demand.

SCOPE OF STUDY:

The report analyzes the Peptide Antibiotics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Non-ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics); Disease Type (Skin Infection, HABP / VABP, Blood Stream Infections, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Acurx Pharmaceuticals
  • ANI Pharmaceuticals, Inc.
  • Antabio
  • BiomX
  • Clarametyx Biosciences
  • Cubist Pharmaceuticals (acquired by Merck & Co.)
  • Cumberland Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GSK plc.
  • Melinta Therapeutics
  • Merck & Co., Inc.
  • MinervaX
  • Pfizer Inc.
  • Sandoz AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • The Menarini Group
  • Venatorx Pharmaceuticals
  • Xellia Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Peptide Antibiotics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Multidrug-Resistant Pathogens Throws the Spotlight on Peptide Antibiotics as Next-Generation Therapeutics
    • Growing Global Burden of Antimicrobial Resistance (AMR) Propels Demand for Novel Peptide-Based Antibiotic Classes
    • Strategic Shifts in Pharmaceutical R&D Portfolios Strengthen Business Case for Peptide Antibiotic Investments
    • Favorable Regulatory Incentives and Fast-Track Designations Accelerate Clinical Development of Peptide Antibiotics
    • Expansion of Hospital-Acquired Infections (HAIs) Worldwide Expands Addressable Market Opportunity for Peptide-Based Solutions
    • Technological Advancements in Peptide Synthesis Drive Down Production Costs and Spur Market Penetration
    • Growing Adoption of Synthetic Biology and Recombinant Technologies Drives Innovation in Peptide Antibiotic Manufacturing
    • Surge in Personalized Medicine and Targeted Therapies Enhances Commercial Viability of Precision-Designed Peptides
    • Growing Interest in Narrow-Spectrum Antibiotics Sustains Growth Momentum for Selective Peptide Therapeutics
    • Increasing Government and Global Health Organization Funding Strengthens Pipeline for Antimicrobial Peptides
    • Demand for Antibiotics With Low Resistance Profiles Generates Strong Interest in Peptide-Based Modalities
    • Rise in Zoonotic and Emerging Infectious Diseases Expands Strategic Use-Cases for Broad-Spectrum Peptide Antibiotics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide Antibiotics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Non-ribosomal Synthesized Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Ribosomal Synthesized Peptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Ribosomal Synthesized Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Skin Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Skin Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Skin Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for HABP / VABP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for HABP / VABP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for HABP / VABP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Blood Stream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Blood Stream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Blood Stream Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Peptide Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Peptide Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Peptide Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Peptide Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Peptide Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Peptide Antibiotics by Product Type - Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Peptide Antibiotics by Product Type - Percentage Breakdown of Value Sales for Non-ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Peptide Antibiotics by Disease Type - Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Peptide Antibiotics by Disease Type - Percentage Breakdown of Value Sales for Skin Infection, HABP / VABP, Blood Stream Infections and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Peptide Antibiotics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Peptide Antibiotics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제